Chester County News and Community Website
CHESTERBROOK, PA — Neuraptive Therapeutics, Inc. announced the enrollment of the first patient in its phase 3 clinical trial evaluating NTX-001, an investigational therapy designed to improve outcomes in patients …
Neuraptive Therapeutics Enrolls First Patient in Phase 3 Trial for NTX-001 Nerve Repair Therapy Read More CHESTERBROOK, PA — Neuraptive Therapeutics, Inc. has announced that its investigational therapy, NTX-001, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). This designation is poised to …
Neuraptive’s NTX-001 Secures Breakthrough Therapy Designation for Nerve Repair Read More WAYNE, PA — Neuraptive Therapeutics, Inc. has unveiled compelling 24-week data from its ongoing NEUROFUSE study on NTX-001, bolstering the product’s status after the positive proof of concept results based …
Neuraptive Therapeutics Reports Encouraging 24-Week Data for NTX-001 in NEUROFUSE Study Read More WAYNE, PA — Neuraptive Therapeutics Inc. recently announced that its novel treatment for peripheral nerve injury, NTX-001, has received Orphan Drug Designation from the United States Food and Drug Administration …
Neuraptive Therapeutics Earns FDA Orphan Drug Designation for Novel Peripheral Nerve Injury Treatment Read More WAYNE, PA — Neuraptive Therapeutics, Inc., a Pennsylvania-based biotech company, recently announced a major breakthrough in the treatment of peripheral nerve injuries. The firm’s successful demonstration of proof-of-concept in the …
Neuraptive Therapeutics’ Groundbreaking Study Paves Way for Improved Peripheral Nerve Injury Treatment Read More